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Abstract
Background: Gel-200 is a cross-linked hyaluronate single-injection device for treatment of osteoarthritis pain in the
knee. This report summarizes new analyses of the safety of retreatment with Gel-200 from the 13-week, pivotal,
multicenter, randomized controlled trial (RCT) followed by an open-label extension trial (OLE).
Methods: 379 patients were enrolled in the RCT [Gel-200; phosphate-buffered saline (PBS)]. Safety of retreatment
with Gel-200 was assessed by comparing adverse events (AEs) and device-related AEs reported through Week 4
following retreatment with Gel-200 to those reported in patients receiving their first injection in the OLE.
Results: 350 patients completed the initial RCT (231 Gel-200; 119 PBS); 258 patients enrolled in the OLE (162 Gel-200;
96 PBS). In total, 202 patients (125 Gel-200; 77 PBS) qualified for retreatment, while 56 (37 Gel-200; 19 PBS) did not.
There were no significant demographic or disease characteristic differences between Gel-200 patients who were and
were not retreated; those who were not eligible for retreatment experienced greater pain relief from Gel-200 in the
RCT by all effectiveness endpoints (all p < 0.001), without differences in their safety profile. In the OLE, the safety of
Gel-200, including percentages of patients who experienced any AEs (p = 0.547) and device-related AEs (p = 0.521), did
not significantly differ between those receiving a second versus a first injection of Gel-200 following PBS in the RCT.
Conclusion: In the OLE, the safety of a second injection of Gel-200 was comparable to that of a first injection and
effectiveness was similar, as previously reported.
Trial registration: ClinicalTrials.gov identification numbers NTC 00449696 and NTC 00450112
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Background
Osteoarthritis (OA) is the most common inflammatory
joint disorder in the world and one of the leading causes
of disability [1]. Intra-articular (IA) injection of hyalur-
onic acid (HA) which is a glycosaminoglycan chain that
occurs naturally within the knee joint, or viscosupple-
mentation, is a widely used treatment for relief of OA
pain in the knee [2, 3]. In addition to the mechanical
effect of HA lubricating the joint and protecting the car-
tilage from mechanical degradation, IA-HA treatment is
believed to exert its therapeutic effect by providing
chondroprotection and anti-inflammatory effect, stimu-
lating endogenous proteoglycan and HA synthesis, limit-
ing subchondral bone changes, and reducing the action
of joint nociceptors [4, 5]. However, recent OA treat-
ment guidelines by American Academy of Orthopaedic
Surgeons (AAOS) and American College of Rheumatol-
ogy (ACR) cast doubt on the utility of this therapy [6, 7].
This stands in contrast to the fact that many clinicians
have found HA to be a valuable treatment option for
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those OA patients with cardiovascular, gastrointestinal,
and metabolic comorbidities which render use of many
systemic drugs unsuitable [8]. Further analysis of clinical
trial data should provide clinicians with more clarity on
the utility of IA - HA over the discrepancy between
guidelines and clinical practice.
Gel-200 (Gel-One®, Seikagaku Corporation, Tokyo,
Japan) is a sterile, transparent, and viscoelastic hydrogel
composed of a cross-linked hyaluronate, a derivative of a
highly purified hyaluronate product. It was approved by
the United States (US) Food and Drug Administration
(FDA) in 2011 for the treatment of OA pain in the knee.
The safety and effectiveness of a single Gel-200 injection
was demonstrated in a 13-week pivotal multicenter ran-
domized controlled trial (RCT) conducted in the US that
recruited 379 OA patients. Analyses of the Western On-
tario and McMaster Universities Osteoarthritis Index
(WOMAC) visual analog scale (VAS) pain and physical
function subscores, Outcome Measures in Rheumatol-
ogy Clinical Trials and Osteoarthritis Research Society
International (OMERACT −OARSI) strict responders,
and physician global assessments of disease activity in
the initial RCT demonstrated statistically significant im-
provements in patients treated with a single injection of
Gel-200 compared with a phosphate-buffered saline
(PBS) control. At 13 weeks, 6.39 mm of treatment differ-
ence demonstrated a statistical significance in a 100-mm
VAS WOMAC pain subscore (p = 0.037), and from
3 weeks through 13 weeks, 7.10 mm of treatment differ-
ence was shown (p = 0.005). Improvements in WOMAC
pain subscore were evident as early as 3 weeks following
injection with more than 40 % improvement from base-
line and continued through 13 weeks. Adverse events
(AEs) were not significantly different between the treat-
ment groups, and no unanticipated treatment-related
serious AEs were reported [9].
Patients who completed the 13-week RCT were eligible
to enroll in the open-label extension (OLE). Patients were
eligible for treatment with Gel-200 at any point while en-
rolled in the extension once they met the eligibility cri-
teria. Retreatment with Gel-200 was shown to be safe for
13 weeks post retreatment by comparing AE data between
treatment groups (retreatment with Gel-200 and initial
treatment with Gel-200 following PBS), although the pre-
vious analysis did not provide in-depth examination of
comparability between the two groups. In addition, a pre-
viously published analysis demonstrated that repeat treat-
ment with Gel-200 for 13 weeks following retreatment
relieved symptomatic OA as effectively as the initial injec-
tion with a favorable safety profile [10]. For 13 weeks post
retreatment, more than 30 mm improvement from base-
line in WOMAC pain subscores persisted. The amount of
pain relief provided by retreatment was greater than that
reported over 13 weeks post initial treatment.
We report the results of additional analyses of the
RCT and OLE data conducted to provide further evi-
dence of the safety of a repeat injection of Gel-200.
Methods
Trial design
Both the RCT, SI-6606/01, and the OLE, Gel/1132, were
approved by a central institutional review board. The
RCT was conducted from August 2006 to December
2007 (last patient visit) at 28 sites in the US, and the
OLE was conducted from March 2007 to May 2008 (last
patient visit) at 23 of those sites in accordance with good
clinical practices. A signed consent form approved by
the institutional review board was obtained for each
patient. These trials were registered with ClinicalTrials.-
gov (identification numbers NTC 00449696 and
NTC 00450112, respectively). Patients were eligible for
enrolment in the 13 week RCT if they had pain >4 weeks,
Kellgren-Lawrence grade 1–3 by X-ray, and WOMAC
pain subscore ≥40 mm. Patients were instructed to use
only those medications during the trial for OA they were
receiving prior to enrolment, as well as not to use any
medications for symptomatic pain relief within the 24 h
prior to each evaluation visit. Patients were randomized
to Gel-200 or PBS in 2:1 ratio and followed up to
13 weeks.
All patients who completed the 13-week RCT were eli-
gible to enroll in OLE following an informed consent to
the extension and retreatment study. Patients who en-
rolled in the extension study did not receive a Gel-200
injection unless and until their WOMAC pain score
again met eligibility for entry into the RCT, ie, ≥40 mm
on VAS in the treated and ≤20 mm in the contralateral
knee, at any time after enrollment or at evaluations at 3,
6, 9, and 13 weeks in the extension phase. After meeting
these criteria, patients received a single injection of Gel-
200 (30 mg cross-linked hyaluronate in 3.0 mL) in the
treated knee at Week 0 of the retreatment phase and
returned for evaluations at Weeks 1, 3, 6, 9, and 13 fol-
lowing reinjection. Patients who did not meet the pain
criteria through Week 13 of the OLE did not receive an-
other injection. All patients remained blinded to the ini-
tial treatment received during the RCT. Patients were
again instructed to use only allowed medications and
not initiate use of any new analgesic or anti-
inflammatory agents during the study, as well as to not
use any medications for symptomatic pain relief within
the 24 h prior to each evaluation visit.
The safety and effectiveness in the 13-week RCT were
assessed retrospectively by the population who received
a second Gel-200 injection (Retreatment Group A) and
who did not receive a second Gel-200 injection (Non-
retreatment Group B)
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The safety of retreatment with Gel-200 was assessed
by comparing the rates of AEs and device-related AEs
reported in the retreatment study through Week 4 in
those patients receiving a second Gel-200 injection
(Retreatment Group A) to the rates among patients re-
ceiving their first Gel-200 injection (ie, PBS patients
from the RCT, PBS–Gel Group C).
Statistical analyses
Analysis populations
Data were analyzed by performing comparisons within 2
separate safety populations, diagramed in Fig. 1. Safety
Population l comprised all patients who received Gel-
200 treatment during the RCT study and were offered
entry into OLE. This included 2 groups:
1) Retreatment Group A: patients who received
treatment with Gel-200 in both the RCT and OLE
2) Nonretreatment Group B: patients who received
treatment with Gel-200 in the RCT and either did
not consent to or never met criteria for retreatment
Safety Population 2 comprised all patients who re-
ceived a Gel-200 injection during the OLE. This popula-
tion included 2 groups of patients:
1) Retreatment Group A: as defined above, patients
who received treatment with Gel-200 in both the
RCT and OLE
2) PBS–Gel Group C: patients who received PBS
during the RCT and Gel-200 during the OLE
Statistical methods
To demonstrate the safety of retreatment with Gel-200,
rates of AEs and device-related AEs up to 28 days after
reinjection were compared between Retreatment Group
A and PBS–Gel Group C using summary statistics and
Fisher’s exact tests.
To assess the suitability of Retreatment Group A for as-
sessment of the safety of retreatment with Gel-200, demo-
graphics and baseline disease characteristics, rates of AEs,
rates of device-related AEs, and primary and major sec-
ondary efficacy endpoints in the initial RCT were com-
pared between Retreatment Group A and Nonretreatment
Group B using descriptive and summary statistics, Fisher’s
exact tests, and t-tests, as appropriate.
Results
Patient population
Of the 350 patients who completed the pivotal RCT and
were eligible to enroll in the OLE, 258 patients (74 %)
enrolled; 92 patients (26 %) did not, including 69 who
received Gel-200 (Fig. 2). Of patients enrolled in the
OLE, 162 (63 %) were previously treated with Gel-200 in
the initial treatment study, 125 patients (48 %) received
a second injection of Gel-200 during the OLE (Retreat-
ment Group A). Of 96 patients who received PBS in the
RCT, 77 (80 %) received a Gel-200 injection in the OLE.
A total of 37 patients who were treated with Gel-200 in
the RCT and enrolled in the OLE did not qualify for
retreatment and were combined with the 69 patients
who received Gel-200 in the RCT but did not enroll in
the OLE, for a total of 106 in Nontreatment Group B.
Demographics of retreatment group A versus
nonretreatment group B during the initial treatment study
There were no significant demographic or baseline dif-
ferences between Retreatment Group A and Nonretreat-
ment Group B (Table 1). The mean age of patients was
approximately 61 years, and approximately 59 % were fe-
male in both groups. The overall physical profile of pa-
tients in both groups was similar, including mean BMI
of 28.4 kg/m2 and 28.3 kg/m2, respectively. The most
common Kellgren-Lawrence score in both groups was 3,
reported by 46.2 % of patients in Nonretreatment Group
B and 58.4 % of patients in Retreatment Group A. The
Fig. 1 Composition of analysis populations
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Fig. 2 Flowchart of patient population, including identity of analysis populations
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mean baseline of WOMAC pain subscores in the study
knee were 68.1 and 69.0, respectively.
Safety during the initial treatment study in retreatment
group A versus nonretreatment group B
The percentages of patients who experienced AEs and
device related AEs in the pivotal RCT were similar be-
tween Retreatment Group A and Nonretreatment Group
B without statistically significant difference (Table 2).
The most common AEs in both groups, reported by
≥5 % of patients, included joint swelling, joint effusion,
arthralgia, and upper respiratory tract infection (URI).
Rates were similar between the 2 groups for all of these
AEs except for URIs, reported by 10.4 % in Retreatment
Group A and 2.8 % in Nonretreatment Group B. Most
common related AEs reported by ≥5 % of patients were
joint swelling, joint effusion, and arthralgia. Rates of
specific related AEs were also similar between the 2
treatment groups. Overall, the profile of the safety data
collected in the RCT was similar between patients who
did and did not receive retreatment with Gel-200 in the
OLE.
Effectiveness during the initial treatment study in
retreatment group A versus nonretreatment group B
For all assessments at all timepoints following initial
treatment in the pivotal RCT (Weeks 3, 6, 9, and 13),
there was a statistically significant difference between
baseline and follow-up VAS WOMAC pain subscores
within each group (all p <0.001). Mean scores and
changes from baseline were also compared between the
2 groups. For all measures at all timepoints following
treatment, mean scores and changes from baseline were
significantly different between analysis groups (Weeks 3,
Table 1 Patient Demographics in Retreatment Group A and Nonretreatment Group B
Nonretreatment Group B Retreatment Group A
(N = 106) (N = 125)
Age, years
Mean (SD) 61.4 (10.00) 60.8 (10.39)
Gender, N (%)
Female 62 (58.5) 74 (59.2)
Male 44 (41.5) 51 (40.8)
Body mass index, kg/m2 (mean ± SD) 28.4 (4.06) 28.3 (4.05)
Kellgren-Lawrence Score - Study Knee [N (%)]
Grade 1 11 (10.4) 10 (8.0)
Grade 2 46 (43.4) 42 (33.6)
Grade 3 49 (46.2) 73 (58.4)
WOMAC pain subscores - Study Knee (mean) 68.1 69.0
No statistically significant difference was identified between groups
Table 2 Overall Summary of Adverse Events in Retreatment Group A and Nonretreatment Group B
Nonretreatment Group B Retreatment Group A
(N = 106) (N = 125)
Events Patients (%) Events Patients (%)
AEs 187 73 (68.9) 233 84 (67.2)
AEs occurring in ≥5 % of patients
Joint swelling 33 27 (25.5) 49 37 (29.6)
Joint effusion 29 24 (22.6) 35 30 (24.0)
Arthralgia 22 17 (16.0) 24 19 (15.2)
Upper respiratory tract infection 3 3 (2.8) 13 13 (10.4)
Related AEs 48 27 (25.5) 59 31 (24.8)
Related AEs occurring in ≥5 % of patients
Joint swelling 15 14 (13.2) 22 15 (12.0)
Joint effusion 13 12 (11.3) 14 12 (9.6)
Arthralgia 9 7 (6.6) 13 10 (8.0)
No statistically significant difference was identified between groups
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6, and 9 for the change from baseline in WOMAC stiff-
ness subscores, p = 0.002; all others, p <0.001). At Week
13, the endpoint in the initial RCT, there were statisti-
cally significant differences (all p <0.001) between mean
results in the 2 analysis groups for all WOMAC sub-
scores, patient and physician global evaluation (Table 3).
In all cases, mean changes from baseline were larger in
Nonretreatment Group B compared with Retreatment
Group A, indicating that patients experienced greater
OA pain relief in Nonretreatment Group B.
Safety of retreatment with Gel-200 in the retreatment study
in retreatment group A versus PBS–Gel-200 group C
The percentages of patients who experienced AEs and
device-related AEs through 28 days following treatment in
the OLE were similar in Retreatment Group A and PBS–
Gel Group C (p = 0.547 and p = 0.521, respectively;
Table 4). The most commonly reported AEs were in the
musculoskeletal and connective tissue disorders system
organ class, with the most common preferred terms, re-
ported by ≥5 % of patients, being joint effusion, arthralgia,
and joint swelling. Rates of specific device-related AEs
were also similar between the 2 treatment groups. Overall,
the safety profile following treatment with Gel-200 in the
OLE was similar between patients receiving a second Gel-
200 injection (retreatment) and those receiving an initial
injection after receiving PBS in the pivotal RCT.
Discussion
A recent meta-analysis of 29 studies of FDA-approved
viscosupplements by Strand et al. demonstrated that
these products are both safe and effective through
26 weeks in patients with symptomatic knee OA, which
included the pivotal RCT of single injection Gel-200
that demonstrated its safety 13 weeks post injection
[11]. Consistent with the findings of this meta-analysis,
a recent consensus statement issued by experts in
Europe also confirmed the safety and effectiveness of
viscosupplementation in clinical practice [12], in con-
trast to consensus statements in the US by AAOS and
Osteoarthritis Research Society International (OARSI)
[6, 13]. However, reports in the literature regarding the
safety and effectiveness of viscosupplementation in
patients with knee OA have been mixed. In a compre-
hensive meta-analysis of 89 trials that compared visco-
supplementation with sham or a nonintervention control
in adults with knee OA, Rutjes et al. reported that visco-
supplementation was associated with a small, clinic-
ally irrelevant benefit and an increased risk of serious
AEs and local AEs; however, the authors also noted
that trial quality was generally low and safety data
were often poorly reported [14]. Another publication
countered that viscosupplementation is safe [8, 15].
Thus, safety data continue to be analyzed for visco-
supplementation products, and this issue has become
more germane as safety of alternative treatments for
knee OA is being debated [16].
Multiple single-injection viscosupplementation prod-
ucts are approved in the US for which the safety of a re-
peat injection has been examined [17–19]. For two of
these products, follow-up occurred for at least 4 weeks
after the reinjection, and 4 weeks of safety data were
used as evidence for safety of a repeat injection. Thus,
although a previously published analysis of the OLE
study had demonstrated safety of a repeat injection of
Gel-200 up to 13 weeks following retreatment [10], the
current analysis examined safety data over 4 weeks fol-
lowing reinjection. The incidences of all AEs and device-
related AEs were similar between patients receiving
retreatment with Gel-200 and those receiving an initial
injection. These results, consistent with the meta-
analysis by Strand et al., indicate that retreatment with
Gel-200 is generally safe and well tolerated [11]. Add-
itionally, when comparing reported AE rates of a repeat
injection of Gel-200 over 13 weeks, AE rates at 4 weeks
were much lower than those over 13 weeks [10]. No
acute AE that may raise a concern on safety of Gel-200
was identified.
The retreatment population rate in this study was
lower than those reported in retreatment studies for
similar products. Fewer patients who completed the piv-
otal Gel-200 RCT received retreatment in the Gel/1132
study. For example, in trials for approved viscosupple-
mentation products Synvisc-One®, MONOVISC®, and
Table 3 Summary of Effectiveness of Gel-200 at Week 13 in Retreatment Group A and Nonretreatment Group B
Outcome Nonretreatment Group B versus Retreatment Group A
Difference (95 % CI) p-value
WOMAC pain subscores 26.1 (19.2, 32.9) <0.001
WOMAC physical function subscores 23.3 (16.4, 30.2) <0.001
WOMAC stiffness subscores 23.9 (16.6, 31.2) <0.001
Total WOMAC score 23.9 (17.2, 30.6) <0.001
Patient global evaluation 23.0 (14.9, 31.2) <0.001
Physician global evaluation 17.6 (10.5, 24.7) <0.001
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EUFLEXXA®, reinjection rates of 63, 65, and 74 %, re-
spectively, were reported, compared with a 53 % reinjec-
tion rate for Gel-200 in the OLE [17–19]. It was
therefore important to determine that the Retreat-
ment Group A was appropriate to include in this
safety evaluation, representing the overall Gel-200
treatment population in the pivotal RCT. Overall, the
patients retreated with Gel-200 in the OLE were
similar to those who were not reinjected. There were
no significant differences in demographics, baseline
characteristics, or safety events reported in the piv-
otal RCT study for those who did and did not re-
ceive a second Gel-200 injection in the following
OLE. These results show that the Retreatment Group
A was an appropriate sample with which to examine
the safety of retreatment with Gel-200. Moveover, pa-
tients who were not reinjected also did not appear to
have any specific safety concerns about Gel-200 that
would have precluded reinjection. Upper respiratory
infections were reported by ≥5 % in patients with
Gel-One in the 13-week RCT, also in patients receiv-
ing PBS, with a similar incidence (4.7 %). In both
treatment groups, all cases were judged as not re-
lated to treatment by investigators. Nonretreatment
patients also did not appear to have any concerns re-
garding effectiveness; patients in Nonretreatment
Group B experienced greater OA pain relief following
Gel-200 during the RCT than patients in Retreat-
ment Group A. Additionally, those patients who did
not consent to enter the OLE had better effectiveness
results at Week 13 in the pivotal study. The high
pain-relieving effect experienced by patients who re-
ceived Gel-200 injection in Nonretreatment Group B
may have contributed to their decision not to enter
the retreatment study (data not shown), as it is
plausible that for many of these patients, no retreat-
ment was needed at the time that it was provided in
the OLE study. Such potential evidence of long-
lasting effectiveness of Gel-200 is consistent with the
reporting of a recent network meta-analysis by
Bannuru et al., which showed that HA injections
were more effective in pain relief than other pharma-
cologic interventions once the effect of PBS injection
serving as an active control was accounted for during
the network meta-analysis [20, 21]. In the case of
Gel-200, the potential evidence for long-lasting anal-
gesic effect of Gel-200 in the RCT is corroborated by
the finding from a previous animal study which
showed that Gel-200 remained in the joint even
28 days after injection [22]. There was no specific
feature in patients who received the second Gel-200
injection. Patient demographic between patients who
received the second Gel-200 injection and those who
did not receive the second Gel-200 injection, were
similar except for pain scores. However, these results
also demonstrate internal consistency with previous
findings from the same trial that those receiving an
initial injection of Gel-200 had a longer time before
meeting the threshold condition for retreatment eligi-
bility than patients receiving PBS [10].
Conclusions
In conclusion, these additional analyses of retreatment
from the OLE have confirmed the safety of Gel-200 fol-
lowing single and repeat injections in both pivotal and
retreatment trials. Acute AEs were much lower and
similar in incidence to non-acute AEs.
Moreover, pain scores before the retreatment indicated
that non-retreated patients reported more improvement
in pain than patients who ultimately received retreat-
ment, suggesting that Gel-200 was sufficiently effective
to obviate the need for retreatment in many patients in
the RCT.
Table 4 Overall Summary of Adverse Events in Retreatment Group A and PBS Gel Group C
PBS Gel–Group C Retreatment Group A
(N = 74) (N = 125)
Events Patients (%) Events Patients (%)
AEs 38 26 (35.1) 76 50 (40.0)
TEAEs occurring in ≥5 % of patients
Joint effusion 7 7 (9.5) 13 13 (10.4)
Arthralgia 6 6 (8.1) 12 12 (9.6)
Joint swelling 7 7 (9.5) 10 10 (8.0)
Related AEs 12 8 (10.8) 31 18 (14.4)
Related AEs occurring in ≥5 % of patients
Arthralgia 5 5 (6.8) 9 9 (7.2)
Joint swelling 3 3 (4.1) 7 7 (5.6)
No statistically significant difference was identified between groups
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